Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, ...

ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced ...

Earlier in his career he held development roles at Sepracor, Inc., Regeneron Pharmaceuticals, Inc. and Merck, Inc. and served as Assistant Professor of Medicine and Director of Critical Care ...

Earlier in his career, Dr. Parsey held roles of increasing responsibility in the field of clinical development at companies including Sepracor, Regeneron and Merck. Dr. Parsey currently serves on ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced the appointment of Merdad Parsey, M.D., Ph.D., to its Board of ...

$3.9 billion was wiped off Sepracor's market capitalization as investors called into question the entire utility of single enantiomers as a means of improving drugs and managing product life cycles.

ZJ Daskalakis has also received speaker funding through Sepracor Inc. and AstraZeneca, and has served on the advisory board for Hoffmann-La Roche Ltd. This work was supported by the Ontario Mental ...